Market's view on Glaxosmithkline
Published on April 2024
- There are mixed expectations on upcoming quarterly results with some hopeful for a positive outcome similar to another pharmaceutical company, while others anticipate less favorable results.
- Concerns exist regarding the recent drop in the stock price, with some watchers unable to determine the cause of the decline.
- A watcher expressed interest in selling shares within a specific price range due to the uncertain direction of the stock.
- Speculation exists about the stock price potentially revisiting a previous lower level, with some watchers considering this unlikely unless it’s a short-term cash necessity.
- Positive developments include the acceptance by the US Food & Drug Administration of a biologics licence application for a meningitis vaccine.
- Phase III data for a new oral treatment option for urogenital gonorrhoea shows 92.6% microbiological success, offering a potential alternative amid growing resistance to existing treatments.
- Long-term data highlighted that Shingrix vaccine continues to provide high protection against shingles for over a decade, with maintained efficacy and no new safety concerns.
- Comments suggest that pharmaceutical companies have faced environmental pressures from the government, with controversial proposals to reduce drug production for environmental reasons, although these were later removed from the draft guidelines.